hypothesis, where X would depend on the availability of funds and the competition and should probably be between 25 and 55%.
In the discussion, J. Peto (Sutton) questioned whether it was realistic in trials of cancer therapy ever to plan a trial on the basis of an expected difference greater than 10%, since most trials, so far, had found differences less than this figure. Mr Most of the trials showed no convincing evidence of a treatment benefit in terms of survival time but in many cases the power of the trials had been low and they could not, therefore, have been expected to show evidence of a benefit that might have been considered plausible.
D. Spiegelhalter (Cambridge) opened the discussion by wondering whether clinicians were grossly optimistic about the likely size of the treatment effect and whether they nevertheless were good at making a reasonable guess at which was the better treatment. It would be interesting to plot the difference for which there would be a 50% power in each trial against the observed difference in each trial. A clear relationship would show how the clinicians' expectations could be translated into a realistic assessment.
J. Peto broadened the discussion to the problem of how to encourage clinicians to participate in trials by making them more 'fun' i.e. interesting and rewarding, for the participants. Some collaborative groups in America have tried to do this by setting up an interesting research environment for their trials and having associated studies of prognostic factors, pharmacological behaviour of drugs, and special subgroups. We should be trying to do the same in this country.
G. Blackledge (Birmingham) said that Mr Buyse's survey was not so discouraging. In quite a lot of the EORTC trials where a null result had been the outcome, this had been useful in showing that additional treatment of some form had not been beneficial, and, many patients were now being spared unnecessary treatment. Mr Buyse replied that negative trials are useful only if they are large enough to ensure that treatment effects which may be missed are smaller than the minimum effects considered to be worthwhile.
The last speaker in the morning session was R. Peto (Oxford) on the subject of Clinical Trial Overviews. These are necessary to pick up effects which are small but nevertheless very worthwhile. When a number of trials address the same question you may, by an overview, get a clear answer to that question. The situation in breast cancer was fortunate. The NATO trial of adjuvant tamoxifen was beginning to look promising and the question arose whether the study should be stopped and the clinicians informed of the pattern that was emerging. It turned out that there were 36 such trials around the world. When the triallists were contacted to see if they would submit data for an overview, practically all of them thought that, while tamoxifen might be delaying recurrence, it was having no effect on survival. In fact the overview showed a real improvement in survival for the tamoxifen treated patients.
Some overviews have shown no difference between treatments. One of the trials assessing the value of post-operative radiotherapy in breast cancer shows no survival difference up to 10 years. It is interesting to contrast this with clinical opinion before the trials and the overview were done. A survey of all the chapters or papers reviewing the evidence for the benefit of radiotherapy showed that surgeons tended to think radiotherapy could be disadvantageous while radiotherapists tended to think the reverse. Mr Buyse has carried out an overview of studies examining whether radiotherapy is of any value in rectal cancer, and the answer seems to be that there may possibly be an improvement of about 5%, but it is not statistically significant. We are just not getting enough patients entered into trials to answer these important questions. Somehow the numbers entering trials have to be increased and trials become a part of routine clinical service. One way of doing this would be to reduce their complexity both in the method of entering patients and in the data to be collected.
M. Van Glabekke (Brussels) asked whether more patients were entered into cardiovascular trials because the treatments were very much less toxic. Mr R. Peto felt that one answer to toxicity was to be much more flexible about the treatment protocols in trials. If one wanted to know if radiotherapy was of value or not, then accept a wide range of radiotherapy techniques, so that clinicians could still enter patients, but give a dose in keeping with their individual idea of what is acceptable.
Mr Freedman said that the MRC had not primarily addressed itself to questions in common cancers, where large trials might be both necessary and worthwhile. Perhaps this was something we should be trying to get the MRC to do. Mr R. Peto agreed, but commented that the radiosensitizer questions were good questions, but the trials were of inadequate size to provide answers. Mr Freedman disagreed with this. The glioma trial with 400 patients showed very clearly that the radiosensitizer was not improving survival to the extent that had been expected. The trials of misonidazole were also conducted in diseases that were not all that common, stage III carcinoma of the cervix and head and neck cancer, both these sites being chosen on scientific grounds because of the ability to monitor local control.
D. Byar (National Cancer Institute) said that the experience in the USA was not very different from that reported by Mr Buyse for Europe. In fact the Cancer Therapy Evaluation Branch of the Treatment Division of the NCI has been taking a soul-searching look at their own clinical trial activity, because of criticisms suggesting that very little had been discovered by the clinical trials programmes in proportion to the amount of money that had been spent. The important question is in which situations do you want these large simple trials and in which situations are other approaches to research more appropriate. Perhaps the focus should be on identifying more carefully the questions that are worth pursuing and then concentrating our effort on them.
Mr R. Peto wound up the morning session by saying that trials that have been done in the past have acted as a considerable restraint upon what people are likely to believe. A more positive side has been that some trials, such as those in leukaemia, have helped to show how chemotherapy can be given optimally. Trials also provide organised series of patients for centralised study and discussion. The MRC, EORTC and NCI have put a lot of effort into trials and on the whole those trials have done more good than harm. We need to choose a few really good questions where a moderate difference in survival might well exist, or there is a difference in toxicity and no difference in survival. If you are doing a trial, your responsibility is not only to get as many patients as you can into your own trial, but to be aware of trials addressing the same question in other countries and to foster such trials.
The afternoon session was devoted to lessons to be learnt from the past that could help achieve the necessary numbers, The trial compared surgery immediately with pre-operative radiotherapy of 500 cGy in 1 fraction or pre-operative radiotherapy of 2,000cGy in 10 fractions. At the time of stopping the trial, the analysis showed no apparent difference between the groups in terms of survival, etc., but did show the effects of some prognostic factors. Patients with mobile tumours pre-operatively had a 48% survival at 5 years compared with 29% for those with tethered tumours. The post-operative Dukes' classification was also important; Dukes' A 70% compared with 36% for Dukes' B and C. Having finished that study, there was debate about whether there should be a larger dose of radiotherapy used, whether radiotherapy should be given pre-operatively or post-operatively, what might be the possible role of chemotherapy, and what the long-term results of the present study might show and what therefore should be the appropriate control group in the second study. It took three years before a new trial was started. This was confined to tethered tumours only and compared immediate surgery with a higher dose of pre-operative radiotherapy, 4,000 cGy in 20 fractions. The predicted entry rate was 100 patients per year but only 40 patients per year have been achieved.
A study for mobile tumours, Dukes' B or C classification, was not started until March 1984. This trial compared immediately surgery with surgery plus post-operative radiotherapy, and was expected to have an entry of 150 patients per year. The entry achieved has been 100 per year.
There were four possible reasons why the rate of patient entry was lower than expected. Firstly, the three-year gap between the end of the first trial and the beginning of the next obviously didn't help. Secondly, since no improvement with pre-operative radiotherapy had been demonstrated in the first trial, some surgeons were put off the idea of using pre-operative radiotherapy again. Also, a third reason, the longer period, 4 weeks, of pre-operative radiotherapy was unpopular with surgeons. The fourth reason was uncertainty whether it was sensible to sub-group patients into different trials. The prognostic difference between mobile and tethered tumours did not necessarily mean that radiotherapy would be more beneficial in one sub-group than in the other. Professor J. Peto strongly supported this last point. An exactly similar mistake had, in his view, been made recently in the MRC childhood leukaemia trials, where less intensive treatment was being given to the minority of patients with the better prognosis and, not randomised, but only giving the most intensive treatment, with two lots of intensification, to patients with the worse prognosis. This presupposes knowledge which they do not have and now will not obtain from the study. Dr Aitken (MRC Head Office) explained that the Council acknowledged the need for large multicentre trials. In order to achieve adequate numbers of patients for cancer trials the Cancer Therapy Committee was already undertaking some joint studies with other groups such as the EORTC, and collaborative links with the UK cancer charities were being developed. However he emphasised that, particularly for the' less common cancers, survival was not the only suitable endpoint. It remained appropriate for the Council's Working Parties to promote smaller trials in these diseases.
R. Collins (Oxford) gave the last paper in the afternoon session. His subject was Acute Myocardial Infarction trials. These trials had been designed to minimise work in order to maximise trial size. The design was simple: testing practical treatments, with only a one-page discharge form and followup mainly through government records in those centres where such records existed. The first study, ISIS 1, was a study of beta-blockade given early in acute myocardial infarction. The study, involving 250 hospitals worldwide and 16,000 randomised patients, demonstrated a reduction in hospital mortality of 15%.
During the 3' years of recruitment into ISIS 1, the ISIS 2 trial was being planned. This study aimed to test the effect of IV streptokinase on mortality after acute myocardial infarction. First, an overview was made of all trials that had been carried out in the past. The generally held view was that streptokinase had no beneficial effect on mortality, and that it might possibly be harmful since it reduced blood clotting and might therefore increase the risk of haemorrhage and stroke. The overview showed a clearly significant reduction in mortality; typically the risk of death in the treated group was reduced by about 20% with 95% confidence interval from about 10% to 30%. Nevertheless it was clear from the sales of streptokinase that it was not being commonly used.
A similar overview of the randomised trials of aspirin in unstable angina (which is a related condition to acute MI), showed that death or re-infarction was 12% in the control group compared with 7.5% in the aspirin treated group.
A 2 x 2 factorial design is therefore used. The treatments tested are very simple: one involves a rapid high-dose infusion of streptokinase given intravenously over one hour, or placebo, and the second involves oral aspirin for a period of one month. It should therefore be possible to assess the effect of streptokinase, the effects of oral aspirin, and to find out whether there is any synergistic effect between the two. It is hoped that the target of about 20,000 patients will have been achieved by the end of 1987.
Dr Kelly (Birmingham) said that what she found depressing about the cancer trials was not only the small numbers but also the very low proportion of patients entering such trials. What proportion of all possibly eligible patients were in the cardiovascular trials? Dr Collins said that it was still only a few per cent. Dr Kelly said that rather than stopping funding for inadequately sized trials, it seemed more necessary to recruit the doctors who are not applying for funds and are not entering patients for trials.
Mr R. Peto pointed out that there must be about a million new cancer patients a year in Europe. It should therefore be possible to recruit large numbers as in the cardiovascular trials, if the right questions are asked. Dr Kelly said that cancer is different in that it is many diseases, not one, and that often cytotoxic drugs are used which may raise problems in the smaller centres.
Professor Armitage then closed the meeting with a summary of what he felt had been the main points to emerge during the day's proceedings.
